{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:15:55Z","timestamp":1791303355024,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncology Practice"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec><jats:title>PURPOSE:<\/jats:title><jats:p> Treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKIs) has improved survival but is associated with significant financial burden. We measured the annual trend in TKI utilization, Medicare gross payment, and patient out-of-pocket (OOP) expenditure from 2007 to 2016. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p> We used SEER linked to Medicare part-D claims data to identify prevalent CML cases from 2007 to 2016. TKI utilization was measured as the proportion of cases with at least one TKI fill in each year. Average TKI gross payment and median per-member per-month OOP expenditure were calculated from claims data and plotted annually from 2007 to 2016. Year-to-year percent change in gross payment and OOP expenditure was compared with inflation indices. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p> The cohort included 3,189 CML cases with at least one TKI claim. The proportion of prevalent patients with a TKI fill in a year increased from 17.9% in 2007 to 52.8% in 2015. The average annual gross payment per 30-day supply of a TKI increased by an average of 12.8% throughout the period from $9,000 to $10,000 US dollars in 2016. There was no increasing trend in median OOP expenditure per 30-day supply, which varied between $450 and $600 US dollars. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION:<\/jats:title><jats:p> Rising TKI use and TKI drug prices place considerable financial pressure on Medicare part-D insurers. Although there was no increasing trend in OOP expenditure, it may be burdensome for Medicare patients who are likely retired on a fixed income. Our findings support legislation that mitigates increasing drug prices to protect the Medicare system and its beneficiaries. <\/jats:p><\/jats:sec>","DOI":"10.1200\/op.20.00967","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T20:05:06Z","timestamp":1620417906000},"page":"e1811-e1820","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":14,"title":["Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia"],"prefix":"10.1200","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7660-6549","authenticated-orcid":false,"given":"Brian","family":"Talon","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes & Policy, University of Illinois at Chicago College of Pharmacy, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-3518","authenticated-orcid":false,"given":"Gregory S.","family":"Calip","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes & Policy, University of Illinois at Chicago College of Pharmacy, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-5367","authenticated-orcid":false,"given":"Todd A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes & Policy, University of Illinois at Chicago College of Pharmacy, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-9042","authenticated-orcid":false,"given":"Lisa K.","family":"Sharp","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes & Policy, University of Illinois at Chicago College of Pharmacy, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology, University of Illinois at Chicago College of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Touchette","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes & Policy, University of Illinois at Chicago College of Pharmacy, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0071"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.31"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.014639"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.6502"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3742"},{"key":"b8","volume-title":"Financial Toxicity and Cancer Treatment (PDQ\u00ae)\u2013Health Professional Version","year":"2016"},{"key":"b9","first-page":"s78","volume":"22","author":"Doshi JA","year":"2016","journal-title":"Am J Manag Care"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4184"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"b12","first-page":"3","volume":"2020","author":"Enewold L","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12612"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3237"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.029"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31050"},{"key":"b18","volume-title":"Generic Competition and Drug Prices","author":"Center for Drug Evaluation and Research","year":"2019"},{"key":"b19","volume-title":"Promoting Competition to Address Pharmaceutical Prices"},{"key":"b20","volume-title":"AbbVie\u2019s New Pan-Genotypic Hepatitis C Drug Mavyret Deeply Underprices the Competition"},{"key":"b21","first-page":"299","volume":"15","author":"Mullard A","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"b22","volume-title":"Why Are Prescription Drug Prices Rising and How Do They Affect the U.S. Fiscal Outlook?"},{"key":"b23","volume-title":"3.6 Million in Medicare Saved More Than $2.1 Billion on Prescription Drugs in the Donut Hole in 2011"},{"key":"b24","volume-title":"Income and Assets of Medicare Beneficiaries, 2016-2035","author":"Jacobson G","year":"2017"},{"key":"b25","first-page":"1140","volume":"25","author":"Phuar HL","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1515\/fhep-2016-0007"},{"key":"b27","volume":"37","author":"Goulart BHL","year":"2019","journal-title":"J Clin Oncol"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1262"},{"key":"b29","first-page":"669","volume":"20","author":"Kaisaeng N","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5091"},{"key":"b31","volume-title":"How a Medicare Part D Inflation Penalty Would Lower Drug Spending for Patients, Taxpayers, and Employers"},{"key":"b32","volume-title":"The Cost of a Cure: Revisiting Medicare Part D and Hepatitis C Drugs"},{"key":"b33","volume-title":"Medicare Part-D Rebate Summary 2014"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.20.00967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:59:47Z","timestamp":1653821987000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.20.00967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1200\/OP.20.00967"],"URL":"https:\/\/doi.org\/10.1200\/op.20.00967","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"2020-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}